This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=116 http://www.lsis.com/goto/r116/rss 2012-02-05T11:11:14+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=116 Background/Aims: The aim of this single-center, open-label study was to assess the absolute bioavailability of an oral (tablet) versus intravenous formulation of almorexant in healthy subjects. Methods: A pilot phase in 3 healthy male subjects, which preceded the main study, consisted of a single 30-min intravenous infusion of 10 mg almorexant. Its objectives were to ensure the tolerability of the intravenous formulation and to select the intravenous dose for the main study. The main study was (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=116 Pulmonary arterial hypertension (PAH) is a debilitating and often fatal disease characterized by a progressive increase in pulmonary vascular resistance that leads to right ventricular failure. Described in this unit is an in vivo model of monocrotaline-induced pulmonary hypertension in rats that can be used to assess the effects of antihypertensive agents on pulmonary artery pressure and right ventricular hypertrophy. Curr. Protoc. Pharmacol. 46:5.56.1-5.56.11. © 2009 by John Wiley & Sons, (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=116 ScienceDaily (Feb. 1, 2012) An experimental drug, clazosentan, reduced the risk of blood vessel spasm in patients with a brain aneurysm, according to research presented at the American Stroke Association's International Stroke Conference 2012. See Also: Health & Medicine Heart Disease Today's Healthcare Anemia Mind & Brain Brain Injury Stroke Multiple Sclerosis Reference Brain damage Stroke Traumatic brain injury Cerebral contusion In patients with a subarachnoid hemorrhage, even after the (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8106215 |-| Title: 3-aza-bicyclo[3.3.0]octane compounds |-| Inventors: Aissaoui; Hamed (Pulversheim, FR), Boss; Christoph (Allschwil, CH), Gude; Markus (Allschwil, CH), Koberstein; Ralf (Lorrach, DE), Sifferlen; Thierry (Wentzwiller, FR) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The invention relates to 3-aza-bicyclo[3.3.0]octane derivatives of the formula (I) wherein R.sup.1, R.sup.2, R.sup.3, and A are as described in the description and their use (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=116 The novel excipient, sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC, CAS 203787-91-1) increases the oral bioavailability of co-formulated ibandronate (IBN, CAS 138926-19). The aim of this study was to investigate the effect of the IBN/SNAC formulation on the steady-state pharmacokinetics of metformin (CAS 657-24-9) and to assess safety and tolerability of IBN/SNAC when dosed in combination with metformin. Twenty-two healthy subjects received metformin on Days 1 to 6. On Day 7, subjects (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=116 BACKGROUND: Paediatric pulmonary hypertension, is an important cause of morbidity and mortality, and is insufficiently characterised in children. The Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension (TOPP) registry is a global, prospective study designed to provide information about demographics, treatment, and outcomes in paediatric pulmonary hypertension. METHODS: Consecutive patients aged 18 years or younger at diagnosis with pulmonary hypertension and increased pulmonary (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=116 Actelion Ltd. s experimental drug macitentan has a œvery high  probability of success in a clinical trial that will be critical for the company s future, Chief Executive Officer Jean-Paul Clozel said. Data from a late-stage trial of the medicine, a successor to Actelion s top-selling lung drug Tracleer, will œrealistically  be released in the second quarter, Clozel said in an interview yesterday in San Francisco. œWhat is important for us is to do everything in order for the trial to (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8093250 |-| Title: 2-aminocarbonyl-pyridine derivatives |-| Inventors: Caroff; Eva (Ranspach-le-Haut, FR), Hilpert; Kurt (Hofstetten, CH), Meyers; Emmanuel (Aarau, CH) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The present invention relates to 2-aminocarbonyl-pyridine derivatives of Formula (I) and their use as P2Y.sub.12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=116 AIMS/HYPOTHESIS: Endothelial dysfunction is important in the development of vascular complications in diabetes. Patients with type 2 diabetes have increased production of the vasoconstrictor and pro-inflammatory peptide, endothelin-1. Short-term intra-arterial administration of endothelin antagonists improves endothelium-dependent vasodilatation in patients with type 2 diabetes. We tested the hypothesis that oral administration of the dual endothelin receptor antagonist, (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=116 Macitentan is a dual endothelin receptor antagonist under phase 3 investigation in pulmonary arterial hypertension. We investigated the effect of cyclosporine (Cs) and rifampin on the pharmacokinetics of macitentan and its metabolites ACT-132577 and ACT-373898 in healthy male subjects. In addition, in vitro studies were performed to investigate interactions between macitentan and its active metabolite ACT-132577 with human organic anion-transporting polypeptides (OATPs). The clinical study (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8071780 |-| Title: 2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide |-| Inventors: Orchard; Michael Glen (Oxfordshire, GB) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The present invention provides novel piperidine derivatives of formula (I), #STR00001# wherein R represents a substituted benzyl group, which are useful as inhibitors of glucosylceramide synthase (GCS). The compounds of the Invention are (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8067419 |-| Title: Piperazines as antimalarial agents |-| Inventors: Binkert; Christoph (Basel, CH), Boss; Christoph (Allschwil, CH), Corminboeuf; Olivier (Allschwil, CH), Grisostomi; Corinna (Allschwil, CH), Meyer; Solange (Schlierbach, FR) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The invention relates to novel piperazine derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=116 TOULOUSE, France and ANN ARBOR, USA, 22 November 2011. Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein ( ˜HDL ) therapies for the treatment of cardiovascular and metabolic diseases, today announced the appointment of Dr. Richard C. Pasternak to the Board of Directors. Dr. Pasternak has had a long-standing research interest in lipid disorders and atherosclerosis, as well as prevention and patterns of practice and disease management. Previously, he (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8048881 |-| Title: Pyrimidine derivatives and their use as P2Y12 receptor antagonists |-| Inventors: Caroff; Eva (Ranspach-le-Haut, FR), Fretz; Heinz (Riehen, CH), Hilpert; Kurt (Hofstetten, CH), Houille; Olivier (Mulhouse, FR), Hubler; Francis (Hegenheim, FR), Meyer; Emmanuel (Aarau, CH) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The invention relates to 4-aminocarbonyl-pyrimidine derivatives and their use as P2Y.sub.12 receptor antagonists in the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=116 Marseille, France, October 31, 2011 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today that the first patient has been treated in a phase II proof-of-concept study to investigate the efficacy and safety of Trophos TRO40303, a novel mitochondria pore modulator, to treat cardiac ischemia-reperfusion injury (IRI) in acute myocardial (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/4e0c7f/pharmaceutical_pri) has announced the addition of Decision Resources, Inc.'s new report "Pharmaceutical Pricing, Reimbursement, and Market Access News in the Second Quarter of 2011" to their offering. Pharmaceutical Pricing, Reimbursement, and Market Access News in the Second Quarter of 2011 In the second quarter of 2011, several governments in major pharmaceutical markets announced plans for (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=116 Marseille, France, October 25, 2011 - Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that Trophos organized two round-table meetings to establish the endpoints and design for phase two proof of concept studies in multiple sclerosis (MS) for novel agents such as Trophos olesoxime that promote neuro-axonal repair and remyelination. The (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8044076 |-| Title: Phenyl derivatives and their use as immunomodulators |-| Inventors: Bolli; Martin (Allschwil, CH), Lehmann; David (Galmiz, CH), Mathys; Boris (Pratteln, CH), Mueller; Claus (Weil am Rhein, DE), Nayler; Oliver (Arlesheim, CH), Steiner; Beat (Domach, CH), Velker; Jorg (Huningue, FR) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The invention relates to phenyl derivatives of formula (I), their preparation and their use as pharmaceutically (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8044044 |-| Title: 4-(1-amino-ethyl)-cyclohexylamine derivatives |-| Inventors: Hubschwerlen; Christian (Durmenach, FR), Rueedi; Georg (Allschwil, CH), Surivet; Jean-Philippe (Kembs, FR), Zumbrunn-Acklin; Cornelia (Basel, CH) |-| Assignee: Actelion Pharmaceutical Ltd. (Allschwil, CH) |-| The invention relates to compounds of formula (I) wherein R.sup.0 represents H or OH; R.sup.1 represents alkoxy; U and W represent N, V represents CH and R.sup.2 represents H or F, or U (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8044055 |-| Title: 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor |-| Inventors: Caroff; Eva (Ranspach-le-Haut, FR), Hilpert; Kurt (Hofstetten, CH), Meyer; Emmanuel (Aarau, CH) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The invention relates to 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y.sub.12 receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/663d14/biotechnology_in_t) has announced the addition of the "Biotechnology in the Netherlands" report to their offering. Biotechnology in the Netherlands industry profile provides market size and segmentation data (value 2006-10, and forecast to 2015), textual and graphical analysis of market growth trends, and macroeconomic information. The profile also contains descriptions of the leading players (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/bf7f10/the_respiratory_di) has announced the addition of Decision Resources, Inc.'s new report "The Respiratory Disease Pipeline: A Competitive Review" to their offering. The Respiratory Disease Pipeline: A Competitive Review Despite the availability of a plethora of symptomatic treatments, many common chronic respiratory diseases - such as asthma and chronic obstructive pulmonary disorder (COPD) - lack (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8039466 |-| Title: 5-hydroxymethyl-oxazolidin-2-one antibacterials |-| Inventors: Hubschwerlen; Christian (Durmenach, FR), Panchaud; Philippe (Allschwil, CH), Specklin; Jean-Luc (Kembs, FR) |-| Assignee: Actelion Pharmaceutical Ltd. (Allschwil, CH) |-| The invention relates to novel chimeric antibiotics of formula I #STR00001# wherein R.sup.1 represents OH, OPO.sub.3H.sub.2 or OCOR.sup.5; R.sup.2 represents H, OH or OPO.sub.3H.sub.2; R.sup.3 represents H or halogen; (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8039474 |-| Title: 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |-| Inventors: Fecher; Anja (Basel, CH), Fretz; Heinz (Riehen, CH), Riederer; Markus (Liestal, CH) |-| Assignee: Actelion Pharmaceutical Ltd. (Allschwil, CH) |-| The invention relates to novel tetrahydro-1H-carbazole derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Cardiopulmonary Measurement database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 16,000 individuals working in Cardiopulmonary Measurement. http:/bit.ly/qq0Fq4. Top 10 Countries for Cardiopulmonary Measurement (ranked by number of senior (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Pulmonary Hypertension database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector. The database currently tags 30,000 individuals working in Pulmonary Hypertension. http:/bit.ly/pTjsek. Top 10 Countries for Pulmonary Hypertension Research (ranked by number of senior researchers) (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=116 Two years ago, the FDA inspected Actelion Pharmaceuticals offices and found the drugmaker failed to follow proper procedures for reporting adverse events and, as a result, about 3,500 patient deaths were never filed with the agency. A follow-up warning letter was issued and, in response, Actelion went to the other extreme - every adverse event mentioning ˜death was effectively dumped with the FDA, regardless of whether there was a reasonable likelihood that its drug was involved. How many (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=116 Activist hedge fund Elliott Advisors has cut its stake in Swiss biotech firm Actelion to under 3 percent, in a sign it has given up trying to force change in the boardroom or push for a sale. The hedge fund, which had built up a stake of around 6 percent, suffered a severe setback at a shareholder meeting in May when it failed to get its nominated candidates elected to the board. It has since been lowering its stake. According to data published on the website of the Swiss stock exchange SIX on (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8022219 |-| Title: 2-hydroxymethy1-3,4,5-trihydroxy-1-(4-pentyloxybenzyl) piperidine as glucosylceramide synthase (Gcs) inhibitor |-| Inventors: Orchard; Michael Glen (Oxfordshire, GB), Scopes; David Ian Carter (Oxfordshire, GB) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The present invention relates to the compound 3,4,5-piperidinetriol, 2-(hydroxymethyl)-1-[(4-(pentyloxy)phenyl)methyl]-, (2S,3S,4R,5S), or a pharmaceutically acceptable salt or (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 LONDON-(BUSINESS WIRE)-Marketed drugs for a range of conditions are subject to in-depth analysis within this new report available on companiesandmarkets.com. Over the next few years an increasing number of pharmaceutical companies will come to mourn the patent expiries of some of their biggest selling marketed products; as revenue streams slide and generic alternatives erode their market share. Comparative Analysis of Marketed Drugs in Major Indications - Patent Cliff to Set Off Intense (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=116 ScienceDaily (Sep. 15, 2011) Researchers at The Scripps Research Institute have found a novel mechanism by which certain viruses such as influenza trigger a type of immune reaction that can severely sicken or kill those infected. See Also: Health & Medicine Influenza Cold and Flu Bird Flu Plants & Animals Bird Flu Research Biology Genetics Reference Spanish flu Natural killer cell Flu vaccine Avian flu This severe immune reaction - called a cytokine storm - floods the tiny air sacs of the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/773815/respiratory_disord) has announced the addition of the "Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries" report to their offering. Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries Respiratory (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 LONDON-(BUSINESS WIRE)-Pharmaceutical R&D is expensive and time consuming, therefore companies enter into partnership agreements to speed up the process and reduce costs. From January 2010-June 2011 there were at least twenty high profile pharmaceutical partnership deal terminations, according to a new report available on companiesandmarkets.com. Pharmaceutical Partnership Deal Terminations (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/dceab1/cystic_fibrosis_c) has announced the addition of GlobalData 's new report "Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering. Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 GlobalData, the industry analysis specialist, has released its new report, Cystic Fibrosis (CF) Therapeutics - Pipeline Assessment and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c172e3/iloprost_key_pat) has announced the addition of the "Iloprost - Key patent, SPC, and data exclusivity expiry (7 country coverage)" report to their offering. Iloprost - Key patent, SPC, and data exclusivity expiry (7 country coverage) Pipeline Selector helps you avoid hours of painstaking reserach by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8012961 |-| Title: Tricyclic antibiotics |-| Inventors: Hubschwerlen; Christian (Durmenach, FR), Rueedi; Georg (Allschwil, CH), Surivet; John-Philippe (Kembs, FR), Zumbrunn-Acklin; Cornelia (Basel, CH) |-| Assignee: Actelion Pharmaceutical Ltd. (Allschwil, CH) |-| The invention relates to antibacterial compounds of formula (I) #STR00001# wherein U represents CH or N; W represents CH or N; R.sup.1 represents alkoxy, halogen or CN; ring A represents a (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 8003654 |-| Title: N-glycinsulfonamide derivatives and uses as orexin receptor antagonists |-| Inventors: Aissaoui; Hamed (Pulversheim, FR), Boss; Christoph (Allschwil, CH), Gude; Markus (Allschwil, CH), Koberstein; Ralf (Lorrach, DE), Sifferlen; Thierry (Wentzwiller, FR), Zumbrunn Acklin; Cornelia (Basel, CH) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The invention relates to novel sulfonamide compounds of the formula (I) #STR00001# and their use (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 7994198 |-| Title: Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |-| Inventors: Ali; Mezher Hussein (Slough, GB), Orchard; Michael Glen (Slough, GB) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| Compounds of formula (I); wherein R represents various substituent groups, are useful as inhibitors of glucosylceramide synthase. #STR00001# text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 7994336 |-| Title: Azetidine compounds as orexin receptor antagonists |-| Inventors: Aissaoui; Hamed (Pulversheim, FR), Boss; Christoph (Allschwil, CH), Gude; Markus (Allschwil, CH), Koberstein; Ralf (Lorrach, DE), Sifferlen; Thierry (Wentzwiller, FR) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The invention relates to novel azetidine compounds of formula (I), wherein R.sup.1, R.sup.2, and X are as described in the description and their use as orexin (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=116 Marseille France, September 8, 2011 - Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment in the pivotal efficacy study of olesoxime in the rare neurodegenerative condition Spinal Muscular Atrophy (SMA). Over 160 patients have been recruited into the trial since its initiation in October 2010. The study (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/717229/the_worlds_top_10) has announced the addition of the "The World's Top 100 Pharmaceutical Companies" report to their offering. Did you know? Dr. Jeremy Levin is Senior Vice President, Strategy, Alliances and Transactions at Bristol-Myers Squibb. The Email Address Format at Orion Corporation is Firstname.Lastname@Orion.Fi On July 21, 2011, Kissei Pharmaceutical Co., Ltd. announced the launch of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/2962a9/cystic_fibrosis_gl) has announced the addition of GlobalData 's new report "Cystic Fibrosis Global Clinical Trials Review, Q2, 2011" to their offering. Cystic Fibrosis Global Clinical Trials Review, Q2, 2011 GlobalData's clinical trial report, Cystic Fibrosis Global Clinical Trials Review, Q1, 2011" provides data on the Cystic Fibrosis clinical trial scenario. This report provides elemental (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=116 Background/Aims: The aim of this study was to compare the pharmacokinetics and tolerability of single doses of the dual orexin receptor antagonist almorexant in Japanese and Caucasian healthy male subjects (n = 10 in each group, body weight matched ±5%). Methods: Almorexant (200 mg) was administered in the morning in the fasted state. The pharmacokinetic parameters of almorexant were calculated by noncompartmental analysis from the plasma concentration data. Results:The pharmacokinetics of (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 7985760 |-| Title: Piperidinetriol derivatives as inhibitors of glycosyceramid synthase |-| Inventors: Ali; Mezher Hussein (Slough, GB), Orchard; Michael Glen (Slough, GB) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| Compounds of formula (I): wherein R represents various substituent groups, are useful as inhibitors of glucosylceramide synthase. #STR00001# text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=116 Marseille, France, August 23 2011 - Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the use of their novel mitochondrial pore modulator, TRO40303, for cytoprotection. The patent provides coverage for the use of Trophos TRO40303 to reduce the cardiac (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=116 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/9ad909/idiopathic_pulmona) has announced the addition of Global Markets Direct's new report "Idiopathic Pulmonary Fibrosis - Pipeline Review, Q4 2010" to their offering. Idiopathic Pulmonary Fibrosis - Pipeline Review, Q4 2010 Global Markets Direct's, Idiopathic Pulmonary Fibrosis Pipeline Review, Q4 2010, provides an overview of the Idiopathic Pulmonary Fibrosis therapeutic pipeline. This report provides (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 7981886 |-| Title: Antibiotics derivatives |-| Inventors: Bur; Daniel (Therwil, CH), Hubschwerlen; Christian (Durmenach, FR), Surivet; Jean-Philippe (Kembs, FR), Zumbrunn-Acklin; Cornelia (Basel, CH) |-| Assignee: Actelion Pharmaceutical Ltd. (Allschwil, CH) |-| The invention relates to antibiotic derivatives of formula I #STR00001# wherein: A represents -O-, S, -C(.dbd.O)-, -C(.dbd.NOR.sup.6)-; Z-B represents NCH.sub.2CH.sub.2, NCOCH.sub.2, NCH.sub.2CO, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=116 United States Patent: 7981924 |-| Title: Thiophene derivatives |-| Inventors: Bolli; Martin (Allschwil, CH), Lehmann; David (Basel, CH), Mathys; Boris (Pratteln, CH), Mueller; Claus (Weil Am Rhein, DE), Nayler; Oliver (Arlesheim, CH), Steiner; Beat (Battwil, CH), Velker; Jorg (Huningue, FR) |-| Assignee: Actelion Pharmaceuticals Ltd. (Allschwil, CH) |-| The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/channels/?query=116 Actelion announced that the primary endpoint - reduction in the number of new active inflammatory lesions in the brain - has been met with its selective S1P1 receptor agonist, ponesimod, in a Phase IIb dose-finding study in patients with relapsing-remitting multiple sclerosis.The study assessed efficacy, safety and tolerability of three ponesimod doses (10 mg, 20 mg or 40 mg) versus placebo, administered orally once daily for 24 weeks. With 464 patients enrolled, this is the largest ever (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=116 The view has been widely held that pepsin-like aspartic proteinases are found only in eukaryotes and not in bacteria. However, a recent bioinformatics search (Rawlings, N.D. & Bateman, A. [2009] BMC Genomics 10, 437) revealed that in 7 out of ?1,000 completely-sequenced bacterial genomes, genes were present encoding polypeptides that displayed the requisite hallmark sequence motifs of pepsin-like aspartic proteinases. The implications of this theoretical observation prompted us to generate (…)